DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a medical stage gene enhancing firm using its novel proprietary ARCUS ® platform to develop in vivo gene enhancing therapies for stylish gene edits, in the present day introduced that it’s going to take part within the following upcoming investor conferences.
Longwood Boston CEO Convention
Date: Monday, October 28, 2024
Time: 11:10 AM ET
Increasing Platform Potential
Format: Panel
Guggenheim Inaugural Healthcare Convention
Date: Monday, November 11, 2024
Time: 3:00 PM ET
Location: InterContinental Boston
Format: Hearth Chat
Webcast Hyperlink: Register Right here
A dwell webcast for the Guggenheim Inaugural Healthcare Convention will even be accessible on Precision’s web site within the Traders part beneath Occasions & Shows at investor.precisionbiosciences.com. An archived replay of the webcasts will likely be out there for about 30 days following the occasion.
About Precision BioSciences (NASDAQ:), Inc.
Precision BioSciences, Inc. is a medical stage gene enhancing firm devoted to enhancing life (DTIL) with its novel and proprietary ARCUS ® genome enhancing platform that differs from different applied sciences in the way in which it cuts, its smaller measurement, and its less complicated construction. Key capabilities and differentiating traits might allow ARCUS nucleases to drive extra supposed, outlined therapeutic outcomes. Utilizing ARCUS, the Firm’s pipeline is comprised of in vivo gene enhancing candidates designed to ship lasting cures for the broadest vary of genetic and infectious illnesses the place no satisfactory remedies exist. For extra details about Precision BioSciences, please go to www.precisionbiosciences.com.
The ARCUS ® platform is getting used to develop in vivo gene enhancing therapies for stylish gene edits, together with gene insertion (inserting DNA into gene to trigger expression/add operate), elimination (eradicating a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (eradicating a big portion of a faulty gene by delivering two ARCUS nucleases in a single AAV).
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20241021549147/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
Supply: Precision BioSciences, Inc.